Stockscreener 앱 받기
0.9351
0.73%
0.0068
시간 외 거래:
.94
0.0049
+0.52%
전일 마감가:
$0.9283
열려 있는:
$0.95
하루 거래량:
169.04K
Relative Volume:
1.01
시가총액:
$29.12M
수익:
$22,000
순이익/손실:
$-61.44M
주가수익비율:
-0.2928
EPS:
-3.1938
순현금흐름:
$-43.64M
1주 성능:
+9.74%
1개월 성능:
+0.39%
6개월 성능:
-59.52%
1년 성능:
-74.52%
1일 변동 폭
$0.8999
$0.962
1주일 범위
$0.835
$0.962
52주 변동 폭
$0.7702
$5.10
센티 바이오사이언시스 Stock (SNTI) Company Profile
명칭
Senti Biosciences Inc
전화
(650) 239-2030
주소
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
0.9351 | 28.91M | 22,000 | -61.44M | -43.64M | -3.1938 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
센티 바이오사이언시스 Stock (SNTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 개시 | H.C. Wainwright | Buy |
| 2025-06-06 | 개시 | Laidlaw | Buy |
| 2022-10-07 | 개시 | Morgan Stanley | Equal-Weight |
센티 바이오사이언시스 주식(SNTI)의 최신 뉴스
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 - Bitget
Cancer conference session will showcase Senti Bio's cell therapy approach - Stock Titan
SNTI: SENTI-202 achieved 50% ORR and 42% CR/CRh with excellent safety in R/R AML Phase 1 trial - TradingView — Track All Markets
SNTI Stock Price, Quote & Chart | SENTI BIOSCIENCES INC (NASDAQ:SNTI) - ChartMill
Growth Review: Will Senti Biosciences Inc outperform small cap indexes2026 Retail & AI Enhanced Execution Alerts - baoquankhu1.vn
Senti Biosciences, Inc. Files Form 8-K Cover Report with NASDAQ Listing Details (April 1, 2026) - Minichart
Senti Biosciences plans holding company reorganization, stock to continue under SNTI - Investing.com India
Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026SEC Filing - TradingView
Senti Biosciences announces holding company reorganization effective by April 16, 2026SEC filing - marketscreener.com
Senti Biosciences Plans Tax-Free Holding Company Reorganization - TipRanks
Senti Biosciences, Inc. has filed documents with the U.S. Securities and Exchange Commission, officially announcing a holding company reorganization plan. - Bitget
Senti Bios to implement tax-free holding company reorganization, shares to convert and continue trading as SNTI - TradingView — Track All Markets
Holding company reorg keeps Senti (NASDAQ: SNTI) stock structure intact - Stock Titan
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies - Bitget
Senti Biosciences publishes CAR circuit research in Cell Systems - Investing.com
Senti Biosciences publishes CAR circuit research in Cell Systems By Investing.com - Investing.com India
Senti Biosciences (SNTI) holder NEA discloses 3.78M-share, 12.1% stake - Stock Titan
Senti Biosciences (NASDAQ:SNTI) Price Target Cut to $11.00 by Analysts at Chardan Capital - Defense World
SNTI.O Technical Analysis & Stock Price Forecast - Intellectia AI
Buy Rating on SENTI-202 Driven by Strong Early AML Efficacy and De-Risking Regulatory Designations Despite Financing Overhang - TipRanks
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Senti Biosciences, Inc. (SNTI) Reports Q4 Earnings - AlphaStreet
Senti Biosciences stock rating held at Buy by H.C. Wainwright - Investing.com Canada
Senti Biosciences stock rating held at Buy by H.C. Wainwright By Investing.com - Investing.com India
Senti Biosciences (NASDAQ: SNTI) advances SENTI-202 gene circuit CAR-NK program - Stock Titan
Senti Biosciences 10-K: Collaboration revenue $0.022M, Net loss $61.44M, EPS $(2.73) - TradingView
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - The Manila Times
Senti Biosciences Q4 revenue misses analyst estimates - tradingview.com
SNTI: Positive SENTI-202 clinical progress, RMAT status, and $61.4M net loss with $16.4M cash - TradingView
Senti Bio (NASDAQ: SNTI) posts 2025 loss as SENTI-202 gains FDA RMAT - Stock Titan
Is Senti Biosciences Inc stock good for income investorsTrade Volume Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference - Bitget
Senti Bio brings early AML cell therapy data to Innate Killer meeting - Stock Titan
Senti Biosciences Amends Lease, Restructures GeneFab Sublease - TipRanks
Senti Biosciences (NASDAQ: SNTI) halves Alameda space and resets lease with GeneFab - Stock Titan
Senti Biosciences, Inc. Enters Lease Amendment and Sublease Amendment with 1430 South Loop Owner, LLC and Genefab, LLC - marketscreener.com
Gains Report: Is Senti Biosciences Inc stock good for income investors2026 Volume Leaders & High Yield Equity Trading Tips - baoquankhu1.vn
Macro Review: Does Senti Biosciences Inc have a sustainable dividendQuarterly Growth Report & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Should I trade or invest in Senti Biosciences Inc2026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Senti Biosciences (SNTI) Stock Analysis Report | Financials & Insights - Benzinga España
Senti Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Senti Biosciences (SNTI) officer has 10,757 shares withheld for taxes - Stock Titan
Senti Biosciences (SNTI) CEO reports 80,666-share tax withholding on RSUs - Stock Titan
Senti Biosciences Inc (SNTI) DEC/2025 Earning Prediction - Intellectia AI
Is Senti Biosciences Inc. stock a buy before product launchesWeekly Risk Report & Low Volatility Stock Recommendations - Naître et grandir
Risk Off: Is Senti Biosciences Inc stock good for income investorsJuly 2025 Levels & Growth Focused Stock Reports - baoquankhu1.vn
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference - Bitget
센티 바이오사이언시스 (SNTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):